Core Points - The company has temporarily used idle raised funds amounting to RMB 30 million for supplementing its working capital, ensuring that it does not affect the progress of the investment projects [1] - The board and supervisory committee have approved the use of these funds, and the sponsor institution has provided verification opinions [1] - As of August 19, 2025, the company has fully returned the temporarily used idle funds of RMB 29,238,079.34 to the designated account [2]

Company Overview - Aojing Medical focuses on the research, production, and sales of high-end medical devices, with main products including artificial bone repair materials and other Class III medical devices [1] - As of August 19, 2025, Aojing Medical's stock price was 21.55 yuan, down 0.51 yuan or 2.31% from the previous trading day [1] Financial Performance - On August 19, the trading volume was 50,382 hands, with a total transaction amount of 110 million yuan [1] - The company announced the return of 29.2381 million yuan of idle raised funds to the designated account, which was initially planned for temporary liquidity support with a usage period of 12 months, but was used for less than a year [1] Capital Flow - On August 19, the net inflow of main funds was 4.0475 million yuan, accounting for 0.14% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds was 5.2782 million yuan, representing 0.18% of the circulating market value [1]

Group 1 - The company announced the convening of the 11th meeting of the 2nd Board of Directors and the 11th meeting of the 2nd Supervisory Board on August 26, 2024 [1] - The meetings approved the proposal to temporarily use part of the idle raised funds to supplement working capital, with a maximum amount of RMB 30 million [1] - The usage period for the idle raised funds is within 12 months from the date of the Board's approval [1] Group 2 - As of August 19, 2025, the company has fully returned the temporarily used idle raised funds amounting to RMB 29,238,079.34 to the special account for raised funds [1] - The company has notified its sponsor institution and the sponsor representative about the return of the raised funds [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码： 688613 证券简称：奥精医疗 公告编号： 2025-040 特此公告。 奥精医疗科技股份有限公司董事会 2025年8月20日 1 奥精医疗科技股份有限公司（以下简称"公司"）于2024年8月26日分别 召开了第二届董事会第十一次会议、第二届监事会第十一次会议，会议审议通 过了《关于公司使用部分闲置募集资金暂时补充流动资金的议案》，同意公司 在确保不影响募集资金投资项目建设进度的前提下，使用闲置募集资金不超过 人民币3,000.00万元暂时用于补充公司流动资金，使用期限为自公司董事会审 议通过之日起12个月内。监事会对上述议案发表了明确的同意意见，保荐机构 对上述事项发表了核查意见。具体内容详见公司于2024年8月27日在上海证券交 易所官网（www.sse.com.cn）披露的《奥精医疗科技股份有限公司关于公司使 用部分闲置募集资金暂时补充流动资金的公告》（公告编号：2024-034）。 根据董事会决议，公司在规定期限内使用29,238,079.34元闲置募集 ...

融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 最近三个交易日，14日-18日，奥精医疗分别获融资买入0.14亿元、0.08亿元、0.18亿元。 8月18日，沪深两融数据显示，奥精医疗获融资买入额0.18亿元，居两市第1243位，当日融资偿还额0.22 亿元，净卖出347.40万元。 ...

Core Viewpoint - The stock of Aojing Medical (688613) has shown a recent increase in price, with a closing price of 20.26 yuan on August 8, 2025, reflecting a rise of 2.22% [1] Financial Performance - Aojing Medical reported a main revenue of 42.46 million yuan for Q1 2025, representing a year-on-year decline of 10.35% [5] - The net profit attributable to shareholders was 104.15 thousand yuan, down 84.99% year-on-year [5] - The company’s gross profit margin stood at 60.71%, which is higher than the industry average of 51.35% [5] Market Activity - On August 8, 2025, the net inflow of main funds was 16.87 million yuan, accounting for 12.36% of the total transaction amount [1] - Retail investors experienced a net outflow of 10.45 million yuan, representing 7.65% of the total transaction amount [1] - The stock's turnover rate was 4.93%, with a total transaction amount of 136 million yuan [1] Financing and Margin Trading - On August 8, 2025, the financing balance was 138 million yuan, with a net purchase of 6.56 million yuan [3] - The company had no short selling activity, with a margin balance of 138 million yuan [3] Industry Comparison - Aojing Medical's total market capitalization is 2.776 billion yuan, significantly lower than the industry average of 11.731 billion yuan [5] - The company has a price-to-earnings ratio of 666.29, which is substantially higher than the industry average of 65.84 [5] - The return on equity (ROE) for Aojing Medical is 0.07%, compared to the industry average of 1.15% [5]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary of company secretaries in the medical consumables sector is 817,000 yuan [2] - Salary distribution among company secretaries is as follows: below 500,000 yuan (30%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (27%), and above 2,000,000 yuan (2%) [2] - The top three highest-paid company secretaries are: Gong Xingliang from Nanwei Medical (2.2161 million yuan), Zhu Yu from Microelectrophysiology (1.6764 million yuan), and Lin Qing from Weigao Orthopedics (1.6142 million yuan) [2] Age and Education Distribution - The age distribution of company secretaries shows that those aged 40-50 constitute 45%, while those over 50 account for 14%, and those aged 30-40 make up 36% [1] - The educational background of company secretaries is as follows: 7% have an associate degree, 45% hold a bachelor's degree, 43% have a master's degree, and 5% possess a doctoral degree [1] Salary Changes - Among company secretaries with over two years of tenure, the largest salary decrease was observed for Bai Xue from Xishan Technology, with a year-on-year decline of 54.09% [2] - The highest salary increase was recorded for Chen Bin from Weili Medical, with a year-on-year increase of 191.72% [2]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary of company secretaries in the medical consumables sector is 817,000 yuan [2] - Salary distribution among company secretaries is as follows: below 500,000 yuan (30%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (27%), and above 2,000,000 yuan (2%) [2] - The top three highest-paid company secretaries are: Gong Xingliang from Nanwei Medical (2.2161 million yuan), Zhu Yu from Microelectrophysiology (1.6764 million yuan), and Lin Qing from Weigao Orthopedics (1.6142 million yuan) [2] Age and Education Distribution - The age distribution of company secretaries shows that those aged 40-50 constitute 45%, while those over 50 account for 14%, and those aged 30-40 make up 36% [1] - The educational background of company secretaries is as follows: 7% have an associate degree, 45% hold a bachelor's degree, 43% possess a master's degree, and 5% have a doctoral degree [1] Salary Changes - The largest salary decrease was observed for Bai Xue from Xishan Technology, with a year-on-year decline of 54.09% [2] - The largest salary increase was recorded for Chen Bin from Weili Medical, with a year-on-year increase of 191.72% [2]

Core Viewpoint - The article provides a comprehensive overview of the Chinese biomedical materials industry, highlighting key listed companies, their business segments, revenue projections, and strategic planning for future growth. Group 1: Overview of Listed Companies - The A-share listed companies in the biomedical materials sector include Guocera Materials, Weigao Orthopedics, Haohai Biological Technology, Lepu Medical, Lanfang Medical, and Xinmai Medical [1] - The industry is characterized by a diverse range of companies focusing on various segments such as biocomposite materials, biopolymers, and biometals [2][3] Group 2: Revenue Projections - For 2024, key revenue figures for selected companies include: - Guocera Materials: 40.47 billion CNY from dental ceramics and biomedical materials [4] - Weigao Orthopedics: 14.51 billion CNY from orthopedic implants [10] - Lepu Medical: 61.03 billion CNY from cardiovascular materials [5] - The overall revenue for the biomedical materials sector is projected to grow, driven by increasing demand for advanced medical solutions [11] Group 3: Business Layout and Performance - Companies like Aojing Medical, Weigao Orthopedics, and Dabo Medical derive nearly 100% of their revenue from biomedical materials, indicating a focused business strategy [9] - The production and sales rates for biomedical materials are generally below 100%, with companies like Aojing Medical and Weigao Orthopedics showing lower production efficiency [11] Group 4: Strategic Planning and Innovation - Leading companies are focusing on technological innovation, market expansion, and integration of the supply chain to maintain competitive advantages [13] - Companies such as Guocera Materials and Weigao Orthopedics are investing in R&D and international market penetration to enhance their product offerings and market share [14][15]

融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 8月4日，沪深两融数据显示，奥精医疗获融资买入额0.15亿元，居两市第929位，当日融资偿还额0.11亿 元，净买入370.38万元。 最近三个交易日，31日-4日，奥精医疗分别获融资买入0.14亿元、0.11亿元、0.15亿元。 ...